Project Name: Aneurin Bevan University Health Board In-Reach Heart Failure (HF) Specialty Registrar (SpR) - Collaborative Working Project (the “CWP”)

Project Summary: 

The main objective of the CWP is to improve the quality of care delivered to Heart Failure (“HF”) patients, at the CW Partner’s Health Board, in line with the National Institute for Clinical Excellence (NICE),1 and European Society of Cardiology (ESC)2 guidance. This CWP will aim to improve the CW Partner’s current hospital-based specialist HF Service through the deployment of an “in-reach” Heart Failure (HF) specialty registrar (SpR) MN37 (the “CWP Role”) to Cardiology Directorate. Should the project prove successful, the Health Board may wish to use the data from this CWP to create a business case for future funding of this extension to the HF service by the NHS.

Planned Milestones: 

  • CWP kick-off meeting.
  • Hire CWP role.
  • Collate baseline data for measuring success of project.
  • Review and measure project success at months 3, 6, 9 and 12.
  • Project report, outcomes summary, wrap up.

Expected Benefits: 

For the Patient:

  • Improved access to evidence based treatment. 
  • A more equitable and consistent care and access to care. 
  • An enhanced experience for patients, and their carers, who live with HF. 
  • Increased access to education on heart failure will enable patients to self manage their condition.
  • A personalised HF care plan will help the patient to self manage their condition.
  • % increase in Patient Reported Outcome Measures (PROMS) and Quality of life (QoL) measures.

For the CW Partner:

  • Increase the overall quality of care and improve equity of access to specialist care for patients with HF.
  • Increase proportion of patients with HF being managed in accordance with the ESC 2021 chronic heart failure guidelines.2
  • A reduction in waiting list time.

For Novartis: 

  • Further opportunities for the appropriate use of cardiology licensed medicines in line with NICE guidelines,1 including Novartis’s medicine. 
  • Improved reputation. 
  • Improved professional and transparent relationship and Health Board between Novartis and the NHS 

Start Date & Duration: February 2024 for 25 months.

FA-11473112 | July 2025